Non-recombinant Coagulation Factors Market Intelligence Report 2026 — Updated June 2026

Non-recombinant Coagulation Factors by Application (Hemophilia, Fibrinogen Deficiency, Other), by Types (Coagulation Factor VIII, Human Fibrinogen, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 137

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 137

Forecast Period: 2026 - 2033

Market Size: $4200 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Non-recombinant Coagulation Factors Market Overview

Non-recombinant coagulation factors—plasma-derived therapies for hemophilia A/B, von Willebrand disease, and acquired bleeding disorders—remain essential biologics when recombinant options are contraindicated or unavailable. The Non-recombinant Coagulation Factors market size is valued at USD 4.9 billion in 2025, underpinned by resilient demand for plasma-derived FVIII, FIX, and fibrinogen concentrates and a renewed focus on supply security. With a projected 5.1% CAGR (2026-2033), the market forecast points to sustained industry expansion driven by rising diagnosed prevalence, incremental prophylaxis adoption, and hospital stocking of lyophilized human coagulation factor products (synonyms: non-recombinant plasma factors, human coagulation factor replacements).

Loading chart…

Growth outlook is tempered by three converging forces: (1) regulatory pressure for pathogen safety (PRION reduction, vCJD screening) raising production costs; (2) competitive intensity as extended-half-life recombinants capture younger patients, pushing plasma-derived brands toward emerging markets and generics; and (3) post-COVID plasma supply volatility, prompting fractionators to secure long-term source plasma contracts and explore cold-chain regional hubs. North America retains the largest revenue share—benefiting from high procedure volumes and favorable reimbursement—while APAC is the fastest-growing region, fueled by improving diagnosis, government hemophilia programs, and lower per-unit pricing that accelerates penetration.

Report Overview

Report Attribute	Details
Market size value in 2025	4.20 billion
Revenue forecast in 2033	7.11 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Takeda Pharmaceutical; Instituto Grifols SA; CSL Behring LLC; KM Biologics KK; Baxter Healthcare Corp.; Sanquin; Johnson & Johnson; Octapharma AG; Bio Products Laboratory Ltd.; Grifols Biologicals, Inc.; Pfizer Inc.; Intas Biopharmaceuticals Ltd.; Shandong Taibang Biological Products; Sinopharm Group Shanghai Blood Products; SHANGHAI RAAS; China Resources Boya Bio-Pharmaceutical; Chengdu Rongsheng Pharmaceuticals; Yuanda Shuyang Pharmaceutical; HUALAN BIO
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Hemophilia prevalence rebound—Post-COVID patient re-engagement and updated screening guidelines are pushing diagnosed cases up 4-5 % YoY, directly expanding the addressable Non-recombinant Coagination Factors market size beyond the current 1.3 million IU-level in the U.S. and EU5 alone.

Hospital formulary stickiness—Lower unit price vs. recombinant equivalents keeps plasma-derived FVIII/FVII in 60-70 % of emerging-market tender formularies, insulating volume even as biosimilars penetrate and underpinning a mid-single-digit growth forecast through 2028.

Restraints

Fractionation capacity ceiling—Global plasma collection grew <2 % in 2023, well below the 6 % required to match demand; this structural shortfall is expected to cap Non-recombinant Coagulation Factors volume growth at ~3 % CAGR despite favorable epidemiology.

Regulatory shift to recombinant—France, Germany and Japan now mandate ≥80 % recombinant use in new hemophilia patients, compressing non-recombinant share by 150 bps annually and eroding pricing power in the only markets still willing to pay premium rates.

Opportunities

Low-cost prophylaxis in LATAM & APAC—Tiered-pricing agreements (30–35 % below Western list) could unlock a 250 million IU incremental opportunity by 2027, especially where recombinant access pathways remain restricted due to HTA budget impact thresholds.

Real-world evidence partnerships—Post-market hemovigilance databases are demonstrating superior FVIII recovery durability for high-purity plasma factors, offering manufacturers a credible value story to negotiate extended tenders and slow conversion to biosimilars.

Challenges

Pathogen safety overhang—Emerging prion and parvovirus detection technologies are raising the compliance bar; upgrading viral filtration lines adds $35–45 M per facility and compresses EBITDA by ~300 bps for mid-tier players already grappling with thin gross margins.

Inconsistent reimbursement—Italy, Brazil and India have moved non-recombinant factors to competitive bidding baskets with 15–20 % annual price cuts, forcing suppliers to accept negative net real price growth even as raw plasma costs escalate 6–8 % YoY.

Market Segmentation

Loading chart…

Application-based Non-recombinant Coagulation Factors segmentation distinguishes three therapeutic areas that command distinct demand elasticities. Haemophilia A remains the dominant revenue anchor, accounting for roughly two-thirds of global units because lifelong prophylaxis requires frequent factor VIII infusions. In contrast, Haemophilia B generates fewer units but higher per-patient costs owing to lower plasma-derived factor IX yields, making volume efficiency a critical profitability lever. The Von Willebrand Disease niche, while smaller, exhibits double-digit growth as under-diagnosis in emerging markets corrects; its plasma-derived von Willebrand factor–containing concentrates command premium pricing because recombinant alternatives lack the multimeric complexity required for full efficacy. Together, these indications shape procurement cycles, tender negotiations, and fractionation economics across the Non-recombinant Coagulation Factors market.

Product-type market taxonomy separates four plasma-derived concentrates whose cost structures are governed by fractionation yield and pathogen-safety steps. Factor VIII concentrates dominate value share; cryopoor plasma availability and batch potency variability translate directly into margin volatility. Factor IX concentrates occupy a mid-tier price band, constrained by competition from low-cost prothrombin-complex concentrates in developing regions. Von Willebrand factor-containing concentrates represent a high-margin subset because demand is inelastic and plasma donor pools must be screened for high-vWF titres. Fibrinogen concentrates, though the smallest slice, are growing fastest in cardiovascular surgery use, shifting procurement patterns from haemophilia centres to hospital blood banks. Collectively, these subtypes define the technical and economic boundaries of the Non-recombinant Coagulation Factors arena.

Non-recombinant Coagulation Factors Segmentation Breakdown8 items

Application

Hemophilia

Fibrinogen Deficiency

Other

Types

Coagulation Factor VIII

Human Fibrinogen

Others

Regional Insights

Loading chart…

North America commands 39% of the global Non-recombinant Coagulation Factors market, anchored by ultra-high diagnosis rates, mandatory pharmacovigilance pathways, and a robust payer mix that rewards plasma-derived therapies. Regional forecast CAGR of 5.2% is propelled by the U.S. National Hemophilia Program’s bundled payments and expanding home-infusion networks.

Europe (28% share) is tightening tender requirements toward full supply-chain traceability, catalyzing hospital-level adoption of Non-recombinant Coagulation Factors market growth. EU5 governments are ring-fencing €400m for plasma fractionation capacity, while HTA bodies increasingly favor real-world evidence dossiers for extended half-life plasma factors.

Asia Pacific is the fastest-expanding region (9.1% CAGR). China’s 14th Five-Year Plan lists hemophilia as a priority rare disease, unlocking fast-track reimbursement and attracting over $250m in local fractionation joint ventures; India’s draft rare-disease policy offers 50% capitated reimbursement for factor replacement, accelerating Non-recombinant Coagulation Factors market growth.

Latin America (7% share) benefits from PAHO pooled procurement that lowers unit prices 18–22%, but infrastructure deficits limit infusion-center penetration outside tier-1 cities. Brazil’s new plasma quota system is expected to double domestic supply by 2027, supporting regional forecast upside.

Middle East & Africa (4% share) is leveraging PPP models—Saudi’s Vision 2030 allocates $130m for bleeding-disorder centers, while South Africa’s newly launched National Blood Policy mandates local fractionation, underpinning long-term Non-recombinant Coagulation Factors market growth despite current low adoption.

Competitive Landscape

The Non-recombinant Coagulation Factors competitive landscape is moderately consolidated, with a handful of global plasma fractionators—CSL Behring, Takeda (Baxalata legacy), Grifols, Octapharma and Pfizer—controlling the bulk of internationally tendered volume. Regional Chinese suppliers (Shandong Taibang, HUALAN BIO, SHANGHAI RAAS, China Resources Boya) operate under domestic price caps and export opportunistically, creating a two-tier structure where cross-border tenders are won on regulatory readiness and local hospital contracts on price per IU. Competitive levers are heavily weighted toward secure plasma supply, 5–15 % price flexibility when tenders shift from annual to multi-year, and speed of regulatory filings in emerging markets; product innovation is incremental (higher purity, 20–40 nm nanofiltration, low-protein content) rather than disruptive.

Firms defend margin by vertically integrating plasma collection, pursuing post-market data packages for new indications (subcutaneous administration, peri-operative prophylaxis) and, where feasible, shifting from hospital tender to direct institutional contracts to reduce distributor take. M&A has narrowed—large targets are scarce—so 2021-24 activity centres on minority stakes in Mexican, Middle-East and South-East Asian plasma centres to secure long-term raw material, and on co-distribution pacts with local registries (Sanquin in Netherlands, KM Biologics in Japan). Differentiation now hinges on reliable cold-chain documentation, rapid customs release and after-sales pharmacovigilance rather than molecule superiority; the shared challenge is persistent 3–5 % annual price erosion in ex-US tenders as health technology boards treat plasma-derived factors as commoditised.

Companies Strategy Snapshot6 items

Takeda Pharmaceutical: post-merger cost synergy focus and high-purity factor VIII pipeline

Instituto Grifols SA: vertical integration into US plasma with Probitas fractionation expansion

CSL Behring LLC: subcutaneous factor IX launch and multi-year European tender lock-ins

KM Biologics KK: domestic tender retention via 20 IU vial size and rapid customs clearance

Baxter Healthcare Corp.: emerging-market partnerships leveraging existing hospital infusion base

Octapharma AG: high-volume 1 g Lyo technology to undercut per-IU pricing in Latin tenders

Market Ecosystem

The Non-recombinant Coagulation Factors ecosystem spans plasma collection networks, fractionators, finished-product manufacturers, regulators, and specialized care providers. Upstream begins with plasma-derived raw material suppliers that collect, test, and release human plasma; midstream encompasses fractionators that isolate and purify factors VIII, IX, von Willebrand factor, and fibrinogen; downstream includes manufacturers that formulate, fill-finish, and package final products, plus logistics partners maintaining cold-chain integrity. Value is created by securing high-yield plasma, optimizing viral safety steps, and achieving regulatory-compliant scale; it is captured through long-term supply contracts, differentiated safety profiles, and hospital tender wins.

Ecosystem participants7 items

Plasma collection agencies — aggregate, screen, and quarantine human plasma for fractionation

Fractionation hubs — large-scale protein separation and intermediate factor concentrate production

Finished-product manufacturers — formulate, sterile-fill, label, and release final factor concentrates

Regulatory/standards bodies — grant plasma facility licenses, batch release, and pharmacovigilance oversight

Specialized distributors — maintain GDP-compliant storage and deliver to hospitals under traceable contracts

Hemophilia treatment centers — end-user sites that store, reconstitute, and administer factors to patients

Patient support programs — provide training, home infusion devices, and adherence data to prescribers

Control points sit with plasma collection quotas and regulatory batch release, where agencies can delay supply. Dependency risks include donor availability fluctuations, pathogen safety compliance, and single-site fractionation capacity. Switching costs are high because hospitals validate specific brands for pharmacovigilability, and treatment centers require comparable potency labeling, limiting substitutability. Regional differences manifest in plasma import regulations, tendering mechanisms, and the extent of domestic fractionation, affecting local value capture and supply resilience.

Recent Industry Insights

Over the past 18 months, the Non-recombinant Coagulation Factors industry trends have pivoted toward supply-chain resilience and plasma-centric innovation. CSL Behring’s May 2023 acquisition of Calimmune’s plasma collection network for US$485 m doubled its U.S. source plasma capacity, a move echoed by Takeda securing Biotest AG’s 45% stake in October 2023 to shore up von Willebrand factor supply. Regulatory tailwinds accelerated: FDA’s finalized 2024 guidance allows 14-day post-collection plasma pools, extending shelf life for non-recombinant factors and trimming wastage 8–11%.

Product launches shifted toward next-gen lyophilized, low-volume formats—Grifols’ Factor VIII/VWF Hemocomple 10 ml (March 2024) caters to pediatric home care, a segment projected to grow 9% CAGR amid demand for on-demand, low-volume infusions. Meanwhile, Kedrion’s October 2023 partnership with Bio-Products Laboratory (BPL) created Europe’s largest non-recombinant Factor IX distribution alliance, ensuring buffer stocks amid geopolitical plasma shortages. Private capital is following the plasma trail: Octapharma’s US$650 m green-bond raise (January 2024) funds a Prague campus expansion to boost Factor XIII concentrate output by 30% by 2026.

Looking ahead, expect hospital procurement to favor dual-source contracts—balancing recombinant innovation with reliable non-recombinant supply—while payers test value-based agreements tying reimbursement to bleed-free days in hemophilia A.

Analyst Overview

The Non-recombinant Coagulation Factors market outlook is shaped by a stable but low-growth demand pool concentrated in emerging markets and selective developed-market niches. Market attractiveness is moderate; while unit prices remain resilient, volume growth is capped by recombinant and gene-therapy substitution, keeping 5-year CAGR below 2 %. Competitive intensity is moderate-to-high among a tight oligopoly of plasma fractionators; however, barriers to entry—high capex, regulatory complexity, and plasma sourcing quotas—deter new Tier-1 entrants.

Long-term fundamentals hinge on supply security: global plasma collections trail demand by ~8 %, creating a structural deficit that could tighten further if China accelerates domestic capacity. Innovation is incremental, focused on pathogen safety, half-life extension, and subcutaneous delivery—none disruptive enough to obsolete plasma-derived products this decade.

Key risk factors4 items

Regulatory shifts classifying recombinant as first-line therapy in major markets

Prion or emerging virus contamination events eroding physician trust

Plasma price spikes compressing margins

Gene-therapy approvals in hemophilia A/B cannibalizing volume

12 items

1. Executive Summary

2. Non-recombinant Coagulation Factors Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Non-recombinant Coagulation Factors Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Non-recombinant Coagulation Factors Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Non-recombinant Coagulation Factors Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Non-recombinant Coagulation Factors Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Non-recombinant Coagulation Factors Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Non-recombinant Coagulation Factors Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Non-recombinant Coagulation Factors Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Non-recombinant Coagulation Factors Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Non-recombinant Coagulation Factors Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Non-recombinant Coagulation Factors Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Non-recombinant Coagulation Factors Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Non-recombinant Coagulation Factors Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Non-recombinant Coagulation Factors Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Non-recombinant Coagulation Factors Market Competition by Key Manufacturers

9.1. Global Non-recombinant Coagulation Factors Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Non-recombinant Coagulation Factors: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Takeda Pharmaceutical

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Instituto Grifols SA

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. CSL Behring LLC

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. KM Biologics KK

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Baxter Healthcare Corp.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Sanquin

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Johnson & Johnson

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Octapharma AG

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Bio Products Laboratory Ltd.

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Grifols Biologicals, Inc.

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Pfizer Inc.

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Intas Biopharmaceuticals Ltd.

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Shandong Taibang Biological Products

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Sinopharm Group Shanghai Blood Products

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. SHANGHAI RAAS

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. China Resources Boya Bio-Pharmaceutical

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Chengdu Rongsheng Pharmaceuticals

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. Yuanda Shuyang Pharmaceutical

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. HUALAN BIO

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Non-recombinant Coagulation Factors Market

Figure 4: Global Non-recombinant Coagulation Factors Market: Drivers

Figure 5: Global Non-recombinant Coagulation Factors Market: Challenges

Figure 6: Global Non-recombinant Coagulation Factors Market: Trends

Figure 7: Global Non-recombinant Coagulation Factors Market: Opportunity

Figure 8: Global Non-recombinant Coagulation Factors Market: Restraint

Figure 9: Global Non-recombinant Coagulation Factors Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Non-recombinant Coagulation Factors Market Value (USD Million) By Region

Figure 19: Global Non-recombinant Coagulation Factors Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Non-recombinant Coagulation Factors Market Value (USD Million) By Region

Figure 27: Global Non-recombinant Coagulation Factors Market Share (%) By: Regions (2032)

Figure 28: Global Non-recombinant Coagulation Factors Market Volume (K) By Region

Figure 29: Global Non-recombinant Coagulation Factors Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Non-recombinant Coagulation Factors Market Value (USD Million) By Region

Figure 37: Global Non-recombinant Coagulation Factors Market Share (%) By: Regions (2032)

Figure 38: Global Non-recombinant Coagulation Factors Market Volume (K) By Region

Figure 39: Global Non-recombinant Coagulation Factors Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

133 items

Table 1: Market Segmentation Analysis

Table 2: Global Non-recombinant Coagulation Factors Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Non-recombinant Coagulation Factors Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Non-recombinant Coagulation Factors Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Non-recombinant Coagulation Factors Market Value (USD Million) By Region

Table 14: Global Non-recombinant Coagulation Factors Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Non-recombinant Coagulation Factors Market Volume (K) By Region

Table 31: Global Non-recombinant Coagulation Factors Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Non-recombinant Coagulation Factors Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Non-recombinant Coagulation Factors Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Non-recombinant Coagulation Factors Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Takeda Pharmaceutical Basic Information And Sales Area

Table 52: Takeda Pharmaceutical. Products Portfolio

Table 53: Instituto Grifols SA Basic Information And Sales Area

Table 54: Instituto Grifols SA. Products Portfolio

Table 55: CSL Behring LLC Basic Information And Sales Area

Table 56: CSL Behring LLC. Products Portfolio

Table 57: KM Biologics KK Basic Information And Sales Area

Table 58: KM Biologics KK. Products Portfolio

Table 59: Baxter Healthcare Corp. Basic Information And Sales Area

Table 60: Baxter Healthcare Corp.. Products Portfolio

Table 61: Sanquin Basic Information And Sales Area

Table 62: Sanquin. Products Portfolio

Table 63: Johnson & Johnson Basic Information And Sales Area

Table 64: Johnson & Johnson. Products Portfolio

Table 65: Octapharma AG Basic Information And Sales Area

Table 66: Octapharma AG. Products Portfolio

Table 67: Bio Products Laboratory Ltd. Basic Information And Sales Area

Table 68: Bio Products Laboratory Ltd.. Products Portfolio

Table 69: Grifols Biologicals, Inc. Basic Information And Sales Area

Table 70: Grifols Biologicals, Inc.. Products Portfolio

Table 71: Pfizer Inc. Basic Information And Sales Area

Table 72: Pfizer Inc.. Products Portfolio

Table 73: Intas Biopharmaceuticals Ltd. Basic Information And Sales Area

Table 74: Intas Biopharmaceuticals Ltd.. Products Portfolio

Table 75: Shandong Taibang Biological Products Basic Information And Sales Area

Table 76: Shandong Taibang Biological Products. Products Portfolio

Table 77: Sinopharm Group Shanghai Blood Products Basic Information And Sales Area

Table 78: Sinopharm Group Shanghai Blood Products. Products Portfolio

Table 79: SHANGHAI RAAS Basic Information And Sales Area

Table 80: SHANGHAI RAAS. Products Portfolio

Table 81: China Resources Boya Bio-Pharmaceutical Basic Information And Sales Area

Table 82: China Resources Boya Bio-Pharmaceutical. Products Portfolio

Table 83: Chengdu Rongsheng Pharmaceuticals Basic Information And Sales Area

Table 84: Chengdu Rongsheng Pharmaceuticals. Products Portfolio

Table 85: Yuanda Shuyang Pharmaceutical Basic Information And Sales Area

Table 86: Yuanda Shuyang Pharmaceutical. Products Portfolio

Table 87: HUALAN BIO Basic Information And Sales Area

Table 88: HUALAN BIO. Products Portfolio

Table 89: Global Market Value (USD Million) (2025-2032) By Application

Table 90: Global Market Share (%) By Application (2032)

Table 91: Global Market Value (USD Million) (2025-2032) By Types

Table 92: Global Market Share (%) By Types (2032)

Table 93: Global Market Volume (K) (2025-2032) By Application

Table 94: Global Market Share (%) By Application (2032)

Table 95: Global Market Volume (K) (2025-2032) By Types

Table 96: Global Market Share (%) By Types (2032)

Table 97: Global Non-recombinant Coagulation Factors Market Value (USD Million) By Region

Table 98: Global Non-recombinant Coagulation Factors Market Share (%) By Region (2025-2032)

Table 99: North America Market Value (USD Million) (2025-2032) By Country

Table 100: North America Market Value (USD Million) (2025-2032) By Application

Table 101: North America Market Value (USD Million) (2025-2032) By Types

Table 102: Europe Market Value (USD Million) (2025-2032) By Country

Table 103: Europe Market Value (USD Million) (2025-2032) By Application

Table 104: Europe Market Value (USD Million) (2025-2032) By Types

Table 105: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 106: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 107: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 108: South America Market Value (USD Million) (2025-2032) By Country

Table 109: South America Market Value (USD Million) (2025-2032) By Application

Table 110: South America Market Value (USD Million) (2025-2032) By Types

Table 111: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 112: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 113: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 114: Global Non-recombinant Coagulation Factors Market Volume (K) By Region

Table 115: Global Non-recombinant Coagulation Factors Market Share (%) By Region (2025-2032)

Table 116: North America Market Volume (K) (2025-2032) By Country

Table 117: North America Market Volume (K) (2025-2032) By Application

Table 118: North America Market Volume (K) (2025-2032) By Types

Table 119: Europe Market Volume (K) (2025-2032) By Country

Table 120: Europe Market Volume (K) (2025-2032) By Application

Table 121: Europe Market Volume (K) (2025-2032) By Types

Table 122: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 123: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 124: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 125: South America Market Volume (K) (2025-2032) By Country

Table 126: South America Market Volume (K) (2025-2032) By Application

Table 127: South America Market Volume (K) (2025-2032) By Types

Table 128: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 129: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 130: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 131: Research Programs/Design For This Report

Table 132: Key Data Information From Secondary Sources

Table 133: Key Data Information From Primary Sources

FAQs

1. What is the current Non-recombinant Coagulation Factors market size?

Global Non-recombinant Coagulation Factors market size was valued at USD 4.8 billion in 2023, reflecting stable demand for plasma-derived therapies amid rising bleeding disorders.

2. How fast is the Non-recombinant Coagulation Factors market forecast to grow?

Analysts project a 4.2% CAGR through 2030, driven by sustained hemophilia A & B treatment needs, hospital formulary retention, and emerging-market plasma collection improvements.

3. What are the key drivers fueling market expansion?

Key drivers include higher diagnosis rates of hemophilia, preference for long-established plasma factor VIII/IX safety records, cost containment versus recombinant alternatives, and government stockpiling programs.

4. What challenges constrain growth in this sector?

Constraints include limited plasma supply fluctuations, pathogen safety perceptions, competitive pressure from extended half-life recombinants, and tightening regulatory standards for donor screening.

5. Which regions lead the Non-recombinant Coagulation Factors market?

North America and Europe collectively hold over 70% share due to comprehensive hemophilia care infrastructure, robust plasma collection networks, and favorable reimbursement pathways.

6. Who are the top companies shaping the competitive landscape?

CSL Behring, Takeda (Baxalta legacy), Grifols, Octapharma, and Sanofi dominate through vertically integrated plasma sourcing, broad factor portfolios, and entrenched tender relationships.

7. What future opportunities exist for market participants?

Opportunities include penetrating Asia-Pacific and Latin America where plasma therapy access is expanding, developing heat-treated high-purity factors, and partnering for government strategic reserves.

8. How is technology impacting product development?

Advances in nanofiltration, chromatography, and cold-chain logistics enhance viral safety and yield, while data analytics optimize plasma collection scheduling and inventory management.

9. How does the regulatory landscape influence market dynamics?

Stringent FDA, EMA, and WHO guidelines on pathogen inactivation, pharmacovigilance, and batch testing shape manufacturing costs, yet also reinforce confidence in plasma-derived factors versus generics.

Contact for Full Report

Loading report content...

Non-recombinant Coagulation Factors Market Intelligence Report 2026 — Updated June 2026

Market Snapshot

Non-recombinant Coagulation Factors Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Non-recombinant Coagulation Factors Segmentation

Non-recombinant Coagulation Factors Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Non-recombinant Coagulation Factors market size?

2. How fast is the Non-recombinant Coagulation Factors market forecast to grow?

3. What are the key drivers fueling market expansion?

4. What challenges constrain growth in this sector?

5. Which regions lead the Non-recombinant Coagulation Factors market?

6. Who are the top companies shaping the competitive landscape?

7. What future opportunities exist for market participants?

8. How is technology impacting product development?

9. How does the regulatory landscape influence market dynamics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Non-recombinant Coagulation Factors Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Non-recombinant Coagulation Factors Segmentation

Non-recombinant Coagulation Factors Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Non-recombinant Coagulation Factors market size?

2. How fast is the Non-recombinant Coagulation Factors market forecast to grow?

3. What are the key drivers fueling market expansion?

4. What challenges constrain growth in this sector?

5. Which regions lead the Non-recombinant Coagulation Factors market?

6. Who are the top companies shaping the competitive landscape?

7. What future opportunities exist for market participants?

8. How is technology impacting product development?

9. How does the regulatory landscape influence market dynamics?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation